当前位置:主页 > 医学论文 > 肿瘤论文 >

宫颈癌组织AKT和P-AKT表达与LMVD相关性及其对新辅助化疗效果预测意义

发布时间:2018-03-25 15:17

  本文选题:宫颈癌 切入点:新辅助化疗 出处:《中华肿瘤防治杂志》2017年13期


【摘要】:目的宫颈癌新辅助化疗(neoadjuvant chemotherapy,NACT)的疗效一直存在争议,PI3K/AKT通路在肿瘤细胞增殖、迁移、侵袭及抗凋亡都起到举足轻重的作用。本研究探讨NACT对宫颈鳞状细胞癌AKT通路中AKT及P-AKT的表达对肿瘤微淋巴管生成的影响,并分析其变化与NACT临床疗效的关系。方法采用免疫组化SP法分别检测2011-03-01-2016-03-31滨州医学院附属医院收治的47例ⅠB2~ⅡB期宫颈鳞癌患者行NACT前后AKT和P-AKT的表达情况及肿瘤微淋巴管密度(lymphatic microvessel density,LMVD)的变化。结果免疫组化检测结果显示,NACT前AK和P-AKT的阳性率分别为93.6%和72.3%,化疗后阳性率分别为44.7%和36.2%,NACT前后比较,AKT和P-AKT表达差异有统计学意义,P0.001。化疗前宫颈鳞癌组织中LMVD计数为20.87±3.31,化疗后宫颈鳞癌组织中LMVD计数为16.47±3.44,化疗后宫颈鳞癌组织中LMVD明显降低,t=6.32,P0.001。化疗前宫颈鳞癌AKT阳性的LMVD为21.14±3.19,高于阴性组(17.00±3.00)。Spearman相关分析显示,化疗前后LMVD的表达(r_s=0.39,P=0.007)与化疗前后P-AKT的表达(r_s=0.66,P0.001)均呈正相关。化疗后LMVD与化疗后AKT的表达呈正相关,r_s=0.58,P0.001。淋巴结转移与化疗前后LMVD均呈正相关(r_s=0.44,P0.001;r_s=0.36,P=0.013)。淋巴结转移的患者化疗前化疗后LMVD均高于淋巴结未转移者。结论化疗前P-AKT的表达及化疗后AKT和P-AKT的表达与肿瘤微淋巴管生成呈正相关,LMVD与淋巴结的转移呈正相关,化疗前P-AKT的表达有可能作为预测宫颈癌新辅助化疗疗效的指标。
[Abstract]:The purpose of neoadjuvant chemotherapy for cervical cancer (neoadjuvant, chemotherapy, NACT) the curative effect has been controversial, the PI3K/AKT pathway in tumor cell migration, proliferation, invasion and apoptosis have played a pivotal role. This study was to investigate the expression of NACT on AKT and P-AKT in cervical squamous cell carcinoma in AKT pathway on tumor lymphangiogenesis effect to analyze the relationship between NACT changes and clinical curative effect. Methods: SP immunohistochemical method was used to detect 2011-03-01-2016-03-31 in Affiliated Hospital of Binzhou Medical College were 47 cases of B2~ stage B cervical squamous cell carcinoma before and after NACT in patients with AKT and P-AKT expression and tumor lymphatic microvessel density (lymphatic microvessel, density, LMVD) changes. Results the results of immunohistochemistry the results showed that the positive rate of NACT AK and P-AKT were 93.6% and 72.3% after chemotherapy, the positive rates were 44.7% and 36.2%, NACT compared AKT and P-AKT table There are statistically significant differences of P0.001., LMVD before chemotherapy in cervical squamous cell carcinoma count was 20.87 + 3.31, 16.47 + 3.44 in the count of LMVD cervical squamous cell carcinoma LMVD cervical squamous cell carcinoma after chemotherapy, chemotherapy harem was significantly lower, t=6.32, P0.001. before chemotherapy of cervical squamous cell carcinoma with AKT positive LMVD was 21.14 + 3.19, higher than the negative group (17 + 3).Spearman correlation analysis showed that the expression of LMVD before and after chemotherapy (r_s=0.39, P=0.007) and the expression of P-AKT before and after chemotherapy (r_s=0.66, P0.001) were positively correlated. After chemotherapy, LMVD and AKT after chemotherapy of r_s= expression was 0.58, lymph node metastasis and chemotherapy before and after P0.001. LMVD were positively correlated (r_s=0.44, P0.001; r_s=0.36, P=0.013). Chemotherapy in patients with lymph node metastasis before LMVD after chemotherapy were higher than those without lymph node metastasis. Conclusion the expression of P-AKT after chemotherapy before chemotherapy and the expression of AKT and P-AKT with tumor lymphangiogenesis was positively related to LM The expression of VD is positively correlated with the metastasis of lymph nodes. The expression of P-AKT before chemotherapy may be an indicator of the efficacy of new adjuvant chemotherapy for cervical cancer.

【作者单位】: 滨州医学院附属医院妇科;
【分类号】:R737.33

【相似文献】

相关期刊论文 前3条

1 张琛;杨清;王玉;;PIK3CB、Akt及p-Akt在子宫内膜癌中的表达及意义[J];中国医科大学学报;2012年06期

2 杨斯钠;张明路;师静;常美英;;血清CA153、CA72-A、CA125、p-AKT、AKT水平联合检测用于子宫内膜肿瘤的评定价值[J];临床合理用药杂志;2014年13期

3 Lee C.M.;Shrieve D.C.;ZempolichK.A. ;D.K. Gaffney;张丽娟;;宫颈癌放疗后人类表皮生长因子受体家族(EGFR,HER2,HER3,HER4)、磷酸化Akt(P-Akt)与临床预后的相关性[J];世界核心医学期刊文摘(妇产科学分册);2006年02期

相关会议论文 前1条

1 张琛;杨清;王玉;;PIK3CB、Akt及p-Akt在子宫内膜癌中的表达及意义[A];中华医学会第十次全国妇产科学术会议妇科肿瘤会场(妇科肿瘤学组、妇科病理学组)论文汇编[C];2012年

相关硕士学位论文 前1条

1 侯晓琳;AKT、P-AKT和BTAK在子宫颈鳞癌发生、发展过程的表达及临床病理意义[D];河北医科大学;2012年



本文编号:1663688

资料下载
论文发表

本文链接:https://www.wllwen.com/yixuelunwen/zlx/1663688.html


Copyright(c)文论论文网All Rights Reserved | 网站地图 |

版权申明:资料由用户25a01***提供,本站仅收录摘要或目录,作者需要删除请E-mail邮箱bigeng88@qq.com